Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts

Moderna reported better-than-expected second-quarter revenue of $142 million and a narrower adjusted loss of $2.13 per share, driven by robust Spring COVID booster sales and $800 million in first-half cost reductions. However, shares declined over 4% premarket after the company lowered its 2025 sales forecast by $300 million at the top end to $1.5 billion-$2.2 billion, citing a shift in UK revenue. The firm is aggressively cutting costs, including a 10% workforce reduction, as it pivots to new mRNA products to offset declining COVID vaccine revenue.

Analysis

Moderna delivered a mixed second-quarter report, characterized by strong operational execution but a weakened forward outlook. The company surpassed Wall Street expectations with revenue of $142 million versus a $112.9 million estimate and posted a narrower-than-expected adjusted loss of $2.13 per share, compared to the projected $2.97. This outperformance was driven by higher-than-anticipated demand for its Spring COVID booster shots and significant cost-cutting initiatives, which yielded $800 million in savings in the first half of 2025. Despite these positive results, the market reacted negatively, with shares falling over 4% premarket. The decline was a direct response to the company reducing its 2025 sales forecast, cutting the top end of the range by $300 million to $1.5 billion to $2.2 billion due to a shift in UK revenue deliveries into 2026. This guidance revision overshadows the quarterly beat and highlights the ongoing challenges in transitioning from its pandemic-era peak. Furthermore, the negligible sales reported for its new RSV vaccine, mRESVIA, and the regulatory uncertainty surrounding its COVID-flu combo shot, cast doubt on the near-term growth potential of its pipeline. In response, management is aggressively rightsizing the company, accelerating operating cost reductions and cutting its global workforce by 10% to improve efficiency amid revenue headwinds.

Key Decisions for Investors

• Investors should recalibrate valuation models to reflect the reduced 2025 sales forecast of $1.5 billion to $2.2 billion, as the negative market reaction indicates that forward guidance is outweighing the Q2 earnings beat.
• Closely monitor the commercial ramp-up of the mRESVIA vaccine and any regulatory progress on the COVID-flu combo shot, as the negligible initial RSV sales and existing regulatory delays amplify execution risk for the post-COVID product pipeline.
• While aggressive cost controls provide a degree of downside protection to earnings, the stock's performance now hinges primarily on the company's ability to successfully commercialize new products to offset the structural decline in COVID-19 revenue.